Kovitz Investment Group Partners LLC Has $2.08 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Kovitz Investment Group Partners LLC raised its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 138.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,755 shares of the company's stock after acquiring an additional 15,515 shares during the period. Kovitz Investment Group Partners LLC's holdings in AstraZeneca were worth $2,084,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Dynamic Advisor Solutions LLC boosted its stake in AstraZeneca by 48.9% during the 2nd quarter. Dynamic Advisor Solutions LLC now owns 13,816 shares of the company's stock valued at $1,077,000 after purchasing an additional 4,535 shares in the last quarter. Sequoia Financial Advisors LLC grew its holdings in AstraZeneca by 6.2% during the second quarter. Sequoia Financial Advisors LLC now owns 30,263 shares of the company's stock worth $2,360,000 after acquiring an additional 1,777 shares during the period. Diversified Trust Co raised its position in AstraZeneca by 22.7% in the second quarter. Diversified Trust Co now owns 5,330 shares of the company's stock worth $416,000 after acquiring an additional 987 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in AstraZeneca by 2.5% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 186,152 shares of the company's stock valued at $14,518,000 after acquiring an additional 4,551 shares during the last quarter. Finally, TRUE Private Wealth Advisors acquired a new stake in AstraZeneca during the second quarter valued at approximately $215,000. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Price Performance

Shares of NASDAQ AZN traded down $1.40 during midday trading on Tuesday, reaching $67.18. 3,531,131 shares of the company traded hands, compared to its average volume of 5,308,330. The stock's 50-day simple moving average is $71.09 and its 200-day simple moving average is $77.01. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The firm has a market cap of $208.30 billion, a PE ratio of 32.81, a PEG ratio of 1.22 and a beta of 0.45.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to analysts' expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business's revenue was up 18.0% on a year-over-year basis. During the same period last year, the firm posted $0.87 EPS. As a group, equities analysts anticipate that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AZN has been the topic of a number of recent analyst reports. Erste Group Bank upgraded shares of AstraZeneca from a "hold" rating to a "buy" rating in a report on Wednesday, September 11th. TD Cowen boosted their price target on AstraZeneca from $90.00 to $95.00 and gave the stock a "buy" rating in a research report on Monday, August 12th. UBS Group raised AstraZeneca from a "sell" rating to a "neutral" rating in a report on Wednesday, November 20th. Finally, Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a "sell" rating to a "hold" rating in a report on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.